About the authors

N S Kryzhova

L Ya Rozhinskaya


  1. Насонов Е.Л. Перспективы применения статинов в ревматологии // РМЖ. 2003. No 23 (195). Т. 11. С. 1273-1276.
  2. Скрипникова И.А. Взаимосвязь генерализованного остеопороза и сердечно-сосудистых заболеваний, обусловленных атеросклерозом у женщин постменопаузального периода // Остеопороз и остеопатии. 2001. No 3, С. 27-33.
  3. Шварц Г.Я. Современное состояние лекарственной терапии атеросклероза // Хим. фарм. журн. 1990. No 8. С. 13-22.
  4. Шварц Г.Я. Фармакотерапия остеопороза. М.: Медицинское информационное агентство, 2002. 368 с.
  5. Шварц Г.Я. Статины и формирование кости // Остеопороз и остеопатии. 2003. No 3. С. 17-20.
  6. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodeling // Osteoporos Int. 2001. V. 12(5). P. 380-384.
  7. Chan K.A., Andrade S.E., Boles M. et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women // Lancet. 2000. V. 355. P. 2185-2188.
  8. Chan M.H., Mak T.W., Chiu R.W. et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. // J. Clin Endocrinol Metab. 2001. Sep. V. 86(9). P. 4556-9.
  9. Garrett I.R., Gutierrez C., Mundy G.R. Statins and bone formation // Curr.Pharm. Design. 2001. V. 7. P. 715-736.
  10. LaCroix A.Z., Cauley J.A., Pettinger M. et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study // Ann Intern Med. 2003. Jul 15. V. 139(2). P. 97-104.
  11. Luckman S.P., Hughes D.E., Coxon F.P. et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GNP-binding proteins, including Ras // J. Bone Miner. Res. 1998. V. 13. P. 581-589.
  12. McClung M., Kiel D., Lindsay R. et al. A 12-Month, dose-response study of atorvastatin effects on bone in postmenopausal women // JBMR - January, 2004. V. 19. Num. 1. P. 11-17.
  13. Meier C.R., Schlienger R.G., Kraenzlin M.E. et al. HMG-CoA reductase inhibitors and the risk of fractures // JAMA. 2000. V. 283. P. 3205-3210.
  14. Mostaza J.M., De la Piedra C., Curiel M.D. et al. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women // Clin Chim Acta. 2001. Jun. V. 308(1-2). P. 133-137.
  15. Mundy G., Garrett R., Harris S. et al. Stimulation of bone formation in vitro and in rodents by statins // Science. 1999. Vol. 286. P. 1946-1949.
  16. Pasco J.A., Kotowicz M.A., Henry M.J. et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study // Arch Intern Med. 2002. Mar. 11. V. 162(5). P. 537-540.
  17. Poli A., Bruschi F., Cesana B. et al. Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women // Obstet Gynecol. 2003. Nov. V. 102(5 Pt 1). P. 922-926.
  18. Rejnmark L., Buus N.H., Vestergaard P. et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women // JBMR. May 2004. V. 19, Num. 5. P. 737-744.
  19. Rejnmark L., Buus N.H., Vestergaard P. et al. Statins decrease bone turnover in postmenopausal women: a cross-sectional study // Eur J Clin Invest. 2002. Aug. V. 32(8). P. 581-9.
  20. Reid I.R., Hague W., Emberson J. et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease // Lancet. 2001. Feb. 17. V. 357(9255). P. 509-512.
  21. Stein E.A., Farnier M., Waldstreicher J. et al. Simvastatin Effects of statins on biomarkers of bone metabolism: a randomised trial // Nutr Metab Cardiovasc Dis. 2001. Apr. V. 11(2). P. 84-87.
  22. Van Beek E., Lowik C., Van der Pluijm G., Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates // J. Bone Miner.Res. 1999. Vol. 14. P. 722-729.
  23. Van Beek E., Pieterman E., Cohen L. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates // Biochem. Biophys. Res. Commun. 1999. V. 264. P. 108-111.
  24. Van Staa T.P., Wegman S., de Vries et al. Use of statins and risk of fractures // JAMA. 2001. V. 285. P. 1850-1855.
  25. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients // JAMA. 2000. V. 283. P. 3211-3216.
  26. Whitfield J.F. Statins: new drugs for treating osteoporosis? // Expert Opin Investig Drugs. 2001. Mar. V. 10(3). P. 409-15. Review.



Abstract - 514

PDF (Russian) - 382




Copyright (c) 2005 Kryzhova N.S., Rozhinskaya L.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies